Crizanlizumab, Voxelotor, and L-Glutamine for Sickle Cell Disease: Effectiveness and Value

Thursday ● March 26, 2020 ● 9:30 am to 4:00 pm ET

Please register to attend our GoToWebinar virtual meeting:
https://attendee.gotowebinar.com/register/7738896504872724237

ICER Staff and Consultants

<table>
<thead>
<tr>
<th>Foluso Agboola, MBBS, MPH*</th>
<th>Catherine Koola, MPH*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Director, Evidence Synthesis, ICER</td>
<td>Program Manager, ICER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Molly Beinfeld, MPH*</th>
<th>Avery Mckenna, BS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Lead, Evidence Synthesis, ICER</td>
<td>Research Assistant, ICER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pamela Bradt, MD, MPH*</th>
<th>Steven D. Pearson, MD, MSc*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chief Scientific Officer, ICER</td>
<td>President, ICER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rick Chapman, PhD, MS*</th>
<th>David Rind, MD, MSc*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Director of Health Economics, ICER</td>
<td>Chief Medical Officer, ICER</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monica Frederick, BS*</th>
<th>Eldon Spackman, PhD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program and Event Coordinator, ICER</td>
<td>Assistant Professor, University of Calgary</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serina Herron-Smith, BA*</th>
<th>Patty Synnott, MALD, MS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Assistant, ICER</td>
<td>Director, Evidence Review, ICER</td>
</tr>
</tbody>
</table>

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.